Thursday, December 31, 2009

Speedy Biodel

Watching CNBC this morning, I noticed that a company was making financial waves for developing some cutting edge treatments for diabetes. Biodel asked the FDA to approve its VIAject fast-acting injectable insulin product. It's currently wrapping up its phase III clinical trials and has reported some very promising results. Biodel has formulated special ingredients along with recombinant human insulin to make it act more like insulin non-diabetics make. VIAject would reportedly treat meal time spikes better and then not "hang on" in the bloodstream as long as other fast acting insulins. Here's a side by side comparison graph that Biodel showed on their website:

No comments: